G. Lugo-Zamudio, L. B. Navarrete-Martínez, C. Salazar, F. G. Reyes-Rodríguez, L. Guerrero-Beltrán, D. Arellano-Álvarez
{"title":"对疑似COVID-19患者进行氯喹门诊治疗,以减轻感染相关症状","authors":"G. Lugo-Zamudio, L. B. Navarrete-Martínez, C. Salazar, F. G. Reyes-Rodríguez, L. Guerrero-Beltrán, D. Arellano-Álvarez","doi":"10.24245/mim.v37i3.4798","DOIUrl":null,"url":null,"abstract":"OBJECTIVE: To establish whether there is clinical improvement with the administration of chloroquine as outpatient treatment in patients suspected of COVID-19 assessed by the reduction of clinical manifestations associated with viral infection. MATERIALS AND METHODS: An experimental study was made in patients suspected of COVID-19 who were attended in the respiratory emergency service of the Hospital Juarez de Mexico from June 1st to July 30th, 2020, who received outpatient treatment with chloroquine. The patients were followed up by telephone to find out their health condition. RESULTS: Fifty patients were included, of which 36 were female. The mean age was 41.1 year;the most frequent symptoms were fever, cough and odynophagia;the most persistent symptom was cough (31 out of 50). Also, 24 patients were positive for SARS-CoV-2 and completed their treatment with chloroquine, with persistent descricough;diarrhea, dysgeusia, and symptoms such as nausea, hypogeusia and headache were documented. No patient required a second evaluation in the emergency room or hospital admissions. CONCLUSIONS: Clinical evidence suggests that chloroquine may be useful in reducing the symptoms associated with SARS-CoV-2 if it is administered in the first five days of the onset of the disease;controlled studies are required to confirm this possibility.","PeriodicalId":35750,"journal":{"name":"Medicina Interna de Mexico","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ambulatory treatment with chloroquine in patients with suspicion of COVID-19 for the reduction of symptoms associated to the infection\",\"authors\":\"G. Lugo-Zamudio, L. B. Navarrete-Martínez, C. Salazar, F. G. Reyes-Rodríguez, L. Guerrero-Beltrán, D. Arellano-Álvarez\",\"doi\":\"10.24245/mim.v37i3.4798\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBJECTIVE: To establish whether there is clinical improvement with the administration of chloroquine as outpatient treatment in patients suspected of COVID-19 assessed by the reduction of clinical manifestations associated with viral infection. MATERIALS AND METHODS: An experimental study was made in patients suspected of COVID-19 who were attended in the respiratory emergency service of the Hospital Juarez de Mexico from June 1st to July 30th, 2020, who received outpatient treatment with chloroquine. The patients were followed up by telephone to find out their health condition. RESULTS: Fifty patients were included, of which 36 were female. The mean age was 41.1 year;the most frequent symptoms were fever, cough and odynophagia;the most persistent symptom was cough (31 out of 50). Also, 24 patients were positive for SARS-CoV-2 and completed their treatment with chloroquine, with persistent descricough;diarrhea, dysgeusia, and symptoms such as nausea, hypogeusia and headache were documented. No patient required a second evaluation in the emergency room or hospital admissions. CONCLUSIONS: Clinical evidence suggests that chloroquine may be useful in reducing the symptoms associated with SARS-CoV-2 if it is administered in the first five days of the onset of the disease;controlled studies are required to confirm this possibility.\",\"PeriodicalId\":35750,\"journal\":{\"name\":\"Medicina Interna de Mexico\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina Interna de Mexico\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24245/mim.v37i3.4798\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Interna de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24245/mim.v37i3.4798","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Ambulatory treatment with chloroquine in patients with suspicion of COVID-19 for the reduction of symptoms associated to the infection
OBJECTIVE: To establish whether there is clinical improvement with the administration of chloroquine as outpatient treatment in patients suspected of COVID-19 assessed by the reduction of clinical manifestations associated with viral infection. MATERIALS AND METHODS: An experimental study was made in patients suspected of COVID-19 who were attended in the respiratory emergency service of the Hospital Juarez de Mexico from June 1st to July 30th, 2020, who received outpatient treatment with chloroquine. The patients were followed up by telephone to find out their health condition. RESULTS: Fifty patients were included, of which 36 were female. The mean age was 41.1 year;the most frequent symptoms were fever, cough and odynophagia;the most persistent symptom was cough (31 out of 50). Also, 24 patients were positive for SARS-CoV-2 and completed their treatment with chloroquine, with persistent descricough;diarrhea, dysgeusia, and symptoms such as nausea, hypogeusia and headache were documented. No patient required a second evaluation in the emergency room or hospital admissions. CONCLUSIONS: Clinical evidence suggests that chloroquine may be useful in reducing the symptoms associated with SARS-CoV-2 if it is administered in the first five days of the onset of the disease;controlled studies are required to confirm this possibility.
期刊介绍:
La revista Medicina Interna de México es el órgano oficial del Colegio de Medicina Interna de México Reserva de Titulo de la Dirección General del Derecho de Autor (SEP) número 04-2001-112110545900.-102 certificado de Licitud de Titulo número 11967 y Certilicado de Licitud de Contenido de la Comisión Catificadora de Publicaciones y Revistas Ilustradas (SeGob) número 8375. AutorIzada por SEPOMEX como Publicación Penódica Registro número PPO9- 0884